GlassScriptPhysician profile
Pervaiz Iqbal
NPI 1083658918
$5,883.64
in general payments reported to CMS, 2019-2025
26 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $434 · 2021: $593 · 2022: $704 · 2023: $928 · 2024: $979 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,018 · Education: $96.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,018.29 |
| Education | $96.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,363.77 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,323.10 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Philips North America LLC | $364.02 | 2019-2022 | |
| Abbott Laboratories | $303.91 | 2021-2023 | Pressurewire |
| Phathom Pharmaceuticals, INC. | $207.52 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $206.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Olympus America INC. | $144.44 | 2024 | Spin Vision Video Processor |
| Lexicon Pharmaceuticals, INC. | $125.00 | 2024 | Inpefa |
| Amgen INC. | $124.99 | 2020 | |
| Baxter Healthcare | $97.56 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| Actelion Pharmaceuticals US, INC. | $89.99 | 2024 | Opsumit, Uptravi |
| Exact Sciences Corporation | $80.14 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.27 | 2019-2025 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $57.47 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $53.89 | 2023 | Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $53.61 | 2023-2025 | |
| Insmed, INC. | $45.06 | 2022 | |
| Mallinckrodt Hospital Products INC. | $29.09 | 2024 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $23.39 | 2023 | Aralast |
| Novo Nordisk INC | $22.61 | 2022 | |
| Shield Therapeutics INC | $22.27 | 2023 | Accrufer |
| Circassia INC. | $19.95 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.61 | 2019 | |
| Boston Scientific Corporation | $13.22 | 2022 | |
| Phadia US INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pervaiz Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.